Abstract:• c‐Myc drives transcription of tRNA processing genes EPRS and LARS essential for tumour progression. • EPRS and LARS facilitate MAS via translational up‐regulation of GOT1 and MDH1 in NB cells. • LMNA interacts with and inhibits c‐Myc activity in tRNA processing, MAS and NB progression. • Therapeutic targeting the LMNA‒c‐Myc interaction by lobeline inhibits tumourigenesis and aggressiveness. Background A series of studies have demonstrated the emerging involvement of transfer RNA (tRNA) processing during the progression of tumours. Nevertheless, the roles and regulating mechanisms of tRNA processing genes in neuroblastoma (NB), the prevalent malignant tumour outside the brain in children, are yet unknown. Methods Analysis of multi‐omics results was conducted to identify crucial regulators of downstream tRNA processing genes. Co‐immunoprecipitation and mass spectrometry methods were utilised to measure interaction between proteins. The impact of transcriptional regulators on expression of downstream genes was measured by dual‐luciferase reporter, chromatin immunoprecipitation, western blotting and real‐time quantitative reverse transcription‐polymerase chain reaction (RT‐PCR) methods. Studies have been conducted to reveal impact and mechanisms of transcriptional regulators on biological processes of NB. Survival differences were analysed using the log‐rank test. Results c‐Myc was identified as a transcription factor driving tRNA processing gene expression and subsequent malate‐aspartate shuttle (MAS) in NB cells. Mechanistically, c‐Myc directly promoted the expression of glutamyl‐prolyl‐tRNA synthetase (EPRS) and leucyl‐tRNA synthetase (LARS), resulting in translational up‐regulation of glutamic‐oxaloacetic transaminase 1 (GOT1) as well as malate dehydrogenase 1 (MDH1) via inhibiting general control nonrepressed 2 or activating mechanistic target of rapamycin signalling. Meanwhile, lamin A (LMNA) inhibited c‐Myc transactivation via physical interaction, leading to suppression of MAS, aerobic glycolysis, tumourigenesis and aggressiveness. Pre‐clinically, lobeline was discovered as a LMNA‐binding compound to facilitate its interaction with c‐Myc, which inhibited aminoacyl‐tRNA synthetase expression, MAS and tumour progression of NB, as well as growth of organoid derived from c‐Myc knock‐in mice. Low levels of LMNA or elevated expression of c‐Myc, EPRS, LARS, GOT1 or MDH1 were linked to a worse outcome and a shorter survival time of clinical NB patients. Conclusions These results suggest that targeting c‐Myc transactivation by LMNA inhibits tRNA processing essential for MAS and tumour progression.

The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers

MBNL1 Regulates the Expression and Alternative Splicing of Genes Enriched in Cell Adhesion and Apoptosis

LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer

Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment.

Function of Microrna-145 and Mechanisms Underlying Its Role in Malignant Tumor Diagnosis and Treatment

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

RNA-binding Protein MBNL2 Regulates Cancer Cell Metastasis Through MiR-182-MBNL2-AKT Pathway.

MBNL1‑AS1 Attenuates Tumor Cell Proliferation by Regulating the Mir‑29c‑3p/bves Signal in Colorectal Cancer.

MiR-362-5p, Which is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI

Down-regulation of MBNL1-AS1 Contributes to Tumorigenesis of NSCLC Via Sponging Mir-135A-5p

Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development

N-mytistoyltransferase 1 and 2 Are Potential Tumor Suppressors and Novel Targets of Mir-182 in Human Non-Small Cell Lung Carcinomas.

MBNL2 Regulates DNA Damage Response Via Stabilizing P21.

Studying the Effect of MBNL1 and MBNL2 Loss in Skeletal Muscle Regeneration

Down-Regulation of lncRNA MBNL1-AS1 Promotes Tumor Stem Cell-like Characteristics and Prostate Cancer Progression through miR-221-3p/CDKN1B/C-myc Axis

MBNL splicing factors regulate the microtranscriptome of skeletal muscles

Targeting c‐Myc transactivation by LMNA inhibits tRNA processing essential for malate‐aspartate shuttle and tumour progression

Bmi-1 Expression Modulates Non-Small Cell Lung Cancer Progression.

Regulatory Networks of LncRNA MALAT-1 in Cancer

LBX2-AS1 as a Novel Diagnostic Biomarker and Therapeutic Target Facilitates Multiple Myeloma Progression by Enhancing mRNA Stability of LBX2

A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation